Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016

Abstract

Background:

Lysergic acid diethylamide (LSD) and psilocybin are serotonergic hallucinogens that are used primarily for recreational abuse. Small studies evaluated the efficacy of LSD and psilocybin for several psychiatric conditions. There are limited safety or toxicity data for either of these substances, especially in large populations.

Methods:

This was a retrospective analysis of single-substance exposures of LSD or psilocybin-containing mushrooms (PcMs) reported to United States poison centers from 1 January 2000 to 31 December 2016. The study describes the most frequent toxicities, management sites, and medical outcomes.

Results:

A total of 5883 PcM and 3554 LSD exposures were included. Most patients were between 13 and 29 years of age (83.9% PcM, 88.9% LSD) and primarily male (77.9% PcM, 74.1% LSD). Most common clinical effects were hallucinations (45.8% PcM, 37.4% LSD), agitation (24.1% PcM, 42.4% LSD), and tachycardia (18.0% PcM, 38.6% LSD). Serious clinical effects were infrequent, but included hyperthermia, seizures, coma, increased serum creatinine, and cardiac arrest. Most patients were treated and released from the emergency department. More LSD patients were admitted to critical care and non-critical care units than PcM patients. Moderate effect was the most frequent outcome for both substances (61.0% PcM, 62.3% LSD).

Conclusion:

These data find that LSD and PcM use occurs primarily in adolescents and young adults, who experience mild to moderate adverse effects. Serious effects are infrequent but can occur. While most LSD and PcM users require only emergency department management, LSD use is more likely to require medical admission.

Keywords

Lysergic acid diethylamide (LSD)psilocybin poison center drug abuse

Get full access to this article

View all access options for this article.

References

American Association of Poison Control Centers (2016) National Poison Data System (NPDS) NPDS Coding Users’ Manual. Version 3.2. Alexandria, USA: American Association of Poison Control Centers.

Berrens

Lammers

White

(2010) Rhabdomyolysis after LSD ingestion. Psychosomatics 51: 356–356.e3.

Bickel

Ditting

Watz

et al . (2005) Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after ‘magic mushroom’ abuse. Eur J Emerg Med 12: 306–308.

Bogenschutz

Forcehimes

Pommy

et al . (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol 29: 289–299.

Carhart-Harris

Bolstridge

Rucker

et al . (2016) Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry 3: 619–627.

Dunkley

EJC

Isbister

Sibbritt

et al . (2003) The Hunter Serotonin Toxicity Criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96: 635–642.

Erowid (2016) Psilocybin, psilocin, and magic mushroom dosage. Erowid.org. Available at: https://erowid.org/plants/mushrooms/mushrooms_dose.shtml (accessed 31 May 2018).

Erowid (2017) LSD dosage. Erowid.org. Available at: https://erowid.org/chemicals/lsd/lsd_dose.shtml (accessed 31 May 2018).

Gasser

Holstein

Michel

et al . (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202: 513–520.

10.

Griffiths

Johnson

Carducci

et al . (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 30: 1181–1197.

11.

Griffiths

Johnson

Richards

et al . (2011) Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. 4 ed. Psychopharmacology 218: 649–665.

12.

Hasler

Grimberg

Benz

et al . (2004) Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology 172: 145–156.

13.

Hoyt

Rasmussen

Giffin

et al . (1999) Poison center data accuracy: A comparison of rural hospital chart data with the TESS database. Toxic Exposure Surveillance System. Acad Emerg Med 6: 851–855.

14.

Kast

(1966) LSD and the dying patient. Chicago Med School Q 26: 80–87.

15.

Kast

(1967) Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatr Q 41: 646–657.

16.

Kast

Collins

(1964) Study of lysergic acid diethylamide as an analgesic agent. Anesth Analg 43: 285–291.

17.

Kelmendi

Corlett

Ranganathan

et al . (2016) The role of psychedelics in palliative care reconsidered: A case for psilocybin. J Psychopharmacol 30: 1212–1214.

18.

Klock

Boerner

Becker

(1974) Coma, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases. West J Emerg Med 120: 183–188.

19.

Lim

Wasywich

Ruygrok

(2012) A fatal case of ‘magic mushroom’ ingestion in a heart transplant recipient. Intern Med J 42: 1268–1269.

20.

Mardal

Johansen

Thomsen

et al . (2017) Advantages of analyzing postmortem brain samples in routine forensic drug screening—Case series of three non-natural deaths tested positive for lysergic acid diethylamide (LSD). Forensic Sci Int 278: e14–e18.

21.

Maslanka

Scott

(1992) LSD overdose in an eight-month-old boy. J Emerg Med 10: 481–483.

22.

Moore

Cohen

Furberg

(2007) Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med 167: 1752–1759.

23.

Moreno

Wiegand

Taitano

et al . (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67: 1735–1740.

24.

Nichols

(2016) Psychedelics. Pharmacol Rev 68: 264–355.

25.

Nichols

Grob

(2018) Is LSD toxic? Forensic Sci Int 284: 141–145.

26.

Orsolini

Papanti

De Berardis

et al . (2017) The ‘Endless Trip’ among the NPS users: Psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry 8: 109–110.

27.

Peden

Macaulay

KEC

Bissett

et al . (1981) Clinical toxicology of ‘magic mushroom’ ingestion. Postgrad Med J 57: 543–545.

28.

Reiche

Hermle

Gutwinski

et al . (2018) Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry 81: 1–10.

29.

Ross

Bossis

Guss

et al . (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol 30: 1165–1180.

30.

Schmid

Enzler

Gasser

et al . (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78: 544–553.

31.

Schulenberg

Johnston

O’Malley

et al . (2017) Monitoring the Future National Survey Results on Drug Use, 1975–2016: Volume II, College Students and Adults Ages 19–55. Ann Arbor: Institute for Social Research, The University of Michigan. Available at: http://monitoringthefuture.org/pubs.html#monographs (accessed 1 January 2018).

32.

Shelton

Hendricks

(2016) Psilocybin and palliative end-of-life care. J Psychopharmacol 30: 1207–1208.

33.

Van Amsterdam

Opperhuizen

van den Brink

(2011) Harm potential of magic mushroom use: A review. Regul Toxicol Pharmacol 59: 423–429.

34.

West

Cameron

O’Reilly

et al . (2008) Accuracy of current clinical diagnosis in recreational drug-related attendance to the emergency department. Emerg Med Australas 20: 333–338.

35.

Winstock

Barratt

Ferris

et al . (2017) Global Drug Survey 2017: Global overview and highlights. N > 115,000. Global Drug Survey. Available at: https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2017_key-findings-report_final.pdf (accessed 31 May 2018).